Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARADIGM CORPARDM · Entity 155143 | Director | June 29, 2018 | July 03, 2018 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | March 12, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARADIGM CORP
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-06-29 | Direct | 97,323 |
Reported balance
After 2018-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-29 · Grant · Acquired 97,323 · Balance 97,323 F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates.
SUPERNUS PHARMACEUTICALS, INC.
Report date March 12, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,413 |
Reported balance
After 2026-03-12 transaction · row 1
1 source rowRow 1 · 2026-03-12 · Sale · Disposed 5,369 · Balance 60,413 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable,
F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2019 Filed Jun 20, 2019 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-017634 · doc4.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:26 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,427 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-010798 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 Underlying: Common Stock · 12,427 shares Expires 2029-02-22 Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 17:26 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 97,323 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001123292-18-000852 · edgar.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,323 Underlying: Common Stock · 97,323 shares Expires 2028-06-29 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 18:34 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 12,248 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0000899243-18-017624 · doc4.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,248 Underlying: Common Stock · 12,248 shares Expires 2028-06-19 F1 · derivative.exercise_date: 33% of such stock option shall vest on the first anniversary of the grant date, and the remainder shall vest in equal monthly installments over the following two year period. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 17:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,613 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-012892 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,613 Underlying: Common Stock · 8,613 shares Expires 2028-02-23 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039590 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:53 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 110,485 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001123292-17-001082 · edgar.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,485 Underlying: Common Stock · 110,485 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 1, 2017, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:55 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012170 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.